Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 266767
Reference Product shall mean that drug product containing a dosage of 800 mg of metaxalone as described in NDA # 13-217.
Target Formulation A shall mean pharmaceutical product for human use developed under this Agreement in solid oral dosage form, containing no more than 640 mg of metaxalone that is bioequivalent to the Reference Product with respect to metaxalone Cmax and AUC and approximately equivalent with respect to metaxalone Tmax, and intended to be dosed with the same frequency as the Reference Product.
Target Formulation B shall mean pharmaceutical product for human use metaxalone developed under this Agreement that is intended to be dosed twice per day.
IPSCIO Record ID: 266766
For the Launch Timing of Authorized Generic Product, the Parties agree that the Authorized Generic Product may only be marketed, distributed or sold by Licensee beginning on the Authorized Generic Launch Date and continuing through the Term of this Agreement.
For the License to Manufacture. Licensor grants a nonexclusive, personal, non-transferable and, nonassignable license under the Licensor Authorized Generic Patent Rights to Manufacture the Authorized Generic Product in the Territory during the Term.
For the License to Commercialize, Licensor grants a non-exclusive, personal, non-transferable and, non-assignable license under the Licensor Authorized Generic Patent Rights to Commercialize the Authorized Generic Product in the Territory during the Term.
For the Assignment, Licensor agrees to, and hereby does, and shall cause each of its employees, consultants, subcontractors, and Affiliates to, assign exclusively to Licensee all right, title, and interest in and to Licensees Manufacturing Equipment Improvements and Licensees Manufacturing Process Improvements developed, conceived, or created by such Licensor Assignors, alone or jointly with others, including all intellectual property rights associated therewith.
IPSCIO Record ID: 260464
The licensed know-how includes studies titled Determination of Metaxalone Metabolism in Expressed Recombinant Human Enzymes; and, Determination of the Inhibitory Potential ofMetaxalone on the Activities ofCYPlA2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2El, and CYP3A4 in Human Liver Microsomes; and, Determination of the induction of CYP1A2, CYP2B6, CYP2A6, CYP2C8, CYP2C9, CYP2Cl 9, CYP2D6, CYP2El , and CYP3A4 activities by Metaxalone in human hepatocytes.
Metaxalone is a skeletal muscle relaxant prescribed for the short-term treatment of painful muscle spasms.
IPSCIO Record ID: 26203
Zaleplon (being N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide)
Botulinum Toxin Type B
Metaxalone is a muscle relaxant used to relax muscles and relieve pain caused by strains, sprains, and other musculoskeletal conditions.
Zaleplon is a sedative-hypnotic, almost entirely used for the management/treatment of insomnia.
Antegren is a humanized monoclonal antibody against the cell adhesion molecule a4-integrin. Natalizumab is used in the treatment of multiple sclerosis and Crohn's disease.
Zonisamide is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents.
(a) to the extent required for Elan to comply in all respects with the Orasense Agreements;
(b) to the extent required for Elan to comply in all respects with the Avlan Agreements;
(c) to the extent required for Elan to comply in all respects with the GlycoGenesys Licence Agreement;
(d) to the extent required for Elan to comply in all respects with the Emisphere Settlement Agreement;
(e) to the extent required for Elan to comply in all respects with the Targeted Genetics Agreements; and
(f) with respect to any and all Elan Exclusive Products.